Scinai Immunotherapeutics (SCNI) has released an update.
Scinai Immunotherapeutics Ltd has successfully held its Annual Meeting of Shareholders, securing approvals for the re-election of its board members, an amendment to increase authorized shares, and an updated executive compensation policy aligning with NASDAQ standards. The company also confirmed Kesselman & Kesselman as its auditors for 2024. These developments reflect Scinai’s ongoing commitment to corporate governance and financial compliance.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.